Ron Najafi

Ron Najafi

Dr. Ramin (Ron) Najafi is a seasoned scientist, entrepreneur, and executive with more than three decades of experience in the pharmaceutical and biotechnology industries. He is the Founder, President, and CEO of Emery Pharma, a leading Contract Research Organization (CRO) specializing in preclinical research, bioanalysis, and regulatory compliance. Under his leadership, Emery Pharma has grown into an FDA-registered, DEA-licensed, and cGMP/GLP-compliant laboratory with robust analytical capabilities including LC-MS, HRMS, NMR, and GC-MS.

Related Posts:

FDA’s Latest Nitrosamine Guidance Reinforces the need for a more Proactive Risk Management for Drug Developers and CDMOs

August 4, 2026

Alameda, California – August 3, 2026 – Emery Pharma today underscored the importance of the U.S. Food and Drug Administration’s July 24, 2026 update to its guidance on nitrosamine drug substance-related impurities (NDSRIs). The revision adds new API-specific entries, including…

When Pharma Meets the Courtroom: Why Neutral Third-Party Material Management Matters in Litigation

January 3, 2026

In pharmaceutical legal disputes – especially patent litigation, product liability cases, and regulatory investigations – the science isn’t the only thing that matters. The integrity of the material itself can determine the integrity of the case. Whether the disputed item…

The Evolution of Gas Chromatography and later GC-MS and LC-MS. One Man’s Journey from Student to CEO

June 27, 2025

By: Dr. Ron NajafiCEO, Emery Pharma. The world of chromatography has undergone a remarkable transformation, evolving from basic ink separation techniques to the sophisticated UPLC connected to HRMS Orbitrap technology we rely on today. This journey is not just a…